The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508

ACS Chemical Biology

Volumn 7, Issue 5, 2012, Pages 811-816

  Baumli, Sonja ^a,b   Hole, Alison J ^a,b   Noble, Martin E M ^a,b   Endicott, Jane A ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAN 508; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN T; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; BINDING KINETICS; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG SELECTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; PLASTICITY; PRIORITY JOURNAL;

AZO COMPOUNDS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIN A; CYCLIN T; CYCLIN-DEPENDENT KINASE 9; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; PYRAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84862097147     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb2004516     Document Type: Article

References (19)

1. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol Genome Biol. 2 RESEARCH0041
2. Wang, S. D., Griffiths, G., Midgley, C. A., Barnett, A. L., Cooper, M., Grabarek, J., Ingram, L., Jackson, W., Kontopidis, G., McClue, S. J., McInnes, C., McLachlan, J., Meades, C., Mezna, M., Stuart, I., Thomas, M. P., Zheleva, D. I., Lane, D. P., Jackson, R. C., Glover, D. M., Blake, D. G., and Fischer, P. M. (2010) Discovery and characterization of 2-anilino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents Chem. Biol. 17, 1111-1121
3. Krystof, V., Cankar, P., Frysova, I., Slouka, J., Kontopidis, G., Dzubak, P., Hajduch, M., Srovnal, J., de Azevedo, W. F., Orsag, M., Paprskarova, M., Rolcik, J., Latr, A., Fischer, P. M., and Strnad, M. (2006) 4-Arylazo-3,5- diamino-1 H -pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects J. Med. Chem. 49, 6500-6509 (Pubitemid 44657444)
4. Liu, X., Shi, S., Lam, F., Pepper, C., Fischer, P. M., and Wang, S. (2012) CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol Int. J. Cancer 130, 1216-1226
5. Nekhai, S., Bhat, U. G., Ammosova, T., Radhakrishnan, S. K., Jerebtsova, M., Niu, X., Foster, A., Layden, T. J., and Gartel, A. L. (2007) A novel anticancer agent ARC antagonizes HIV-1 and HCV Oncogene 26, 3899-3903 (Pubitemid 46878134)
6. Chen, R., Wierda, W. G., Chubb, S., Hawtin, R. E., Fox, J. A., Keating, M. J., Gandhi, V., and Plunkett, W. (2009) Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia Blood 113, 4637-4645
7. Bettayeb, K., Baunbæk, D., Delehouze, C., Loaëc, N., Hole, A. J., Baumli, S., Endicott, J. A., Douc-Rasy, S., Bénard, J., Oumata, N., Galons, H., and Meijer, L. (2010) CDK inhibitors Roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma Cells Genes Cancer 1, 369-380
8. Manohar, S. M., Rathos, M. J., Sonawane, V., Rao, S. V., and Joshi, K. S. (2011) Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription Leukemia Res. 35, 821-830
9. Wang, S. and Fischer, P. M. (2008) Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol. Sci. 29, 302-313
10. Krystof, V., Chamrad, I., Jorda, R., and Kohoutek, J. (2010) Pharmacological targeting of CDK9 in cardiac hypertrophy Med. Res. Rev. 30, 646-666
11. Krystof, V., Rarova, L., Liebl, J., Zahler, S., Jorda, R., Voller, J., and Cankar, P. (2011) The selective P-TEFb inhibitor CAN508 targets angiogenesis Eur. J. Med. Chem. 46, 4289-4294
12. Baumli, S., Lolli, G., Lowe, E. D., Troiani, S., Rusconi, L., Bullock, A. N., Debreczeni, J. E., Knapp, S., and Johnson, L. N. (2008) The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation EMBO J. 27, 1907-1918
13. Baumli, S., Endicott, J. A., and Johnson, L. N. (2010) Halogen bonds form the basis for selective P-TEFb inhibition by DRB Chem. Biol. 17, 931-936
14. Tahirov, T. H., Babayeva, N. D., Varzavand, K., Cooper, J. J., Sedore, S. C., and Price, D. H. (2010) Crystal structure of HIV-1 Tat complexed with human P-TEFb Nature 465, 747-751
15. Vedadi, M., Niesen, F. H., Allali-Hassani, A., Fedorov, O. Y., Finerty, P. J., Jr., Wasney, G. A., Yeung, R., Arrowsmith, C., Ball, L. J., Berglund, H., Hui, R., Marsden, B. D., Nordlund, P., Sundstrom, M., Weigelt, J., and Edwards, A. M. (2006) Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination Proc. Natl. Acad. Sci. U.S.A. 103, 15835-15840 (Pubitemid 44657553)
16. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9, 28-39
17. Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., and Kuriyan, J. (2011) Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms Mol. Cell 42, 9-22
18. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases Cell 109, 275-282 (Pubitemid 34606870)
19. Brown, N. R., Noble, M. E., Endicott, J. A., and Johnson, L. N. (1999) The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases Nat. Cell Biol. 1, 438-443 (Pubitemid 129502811)